Ameritas Advisory Services LLC Lowers Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Ameritas Advisory Services LLC lowered its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 11.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,048 shares of the biopharmaceutical company’s stock after selling 1,759 shares during the period. Ameritas Advisory Services LLC’s holdings in Bristol Myers Squibb were worth $824,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Pinney & Scofield Inc. purchased a new position in Bristol Myers Squibb during the 4th quarter valued at about $25,000. Park Square Financial Group LLC bought a new position in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $26,000. Global Wealth Strategies & Associates increased its holdings in Bristol Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 275 shares during the period. Transce3nd LLC bought a new position in Bristol Myers Squibb in the fourth quarter worth approximately $28,000. Finally, Fairway Wealth LLC purchased a new stake in Bristol Myers Squibb during the fourth quarter worth $28,000. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $47.64 on Thursday. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. The company’s fifty day moving average price is $47.78 and its 200-day moving average price is $53.75. Bristol Myers Squibb Company has a 1-year low of $39.35 and a 1-year high of $63.33. The firm has a market capitalization of $96.95 billion, a PE ratio of 17.84, a price-to-earnings-growth ratio of 1.41 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to analysts’ expectations of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The firm’s revenue was down 5.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($4.40) EPS. On average, equities research analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be given a $0.62 dividend. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.21%. Bristol Myers Squibb’s dividend payout ratio is currently 92.88%.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the firm’s stock in a transaction on Friday, April 25th. The stock was acquired at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president owned 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.09% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on BMY shares. Jefferies Financial Group reduced their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research report on Wednesday, April 23rd. William Blair reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Friday, April 25th. Piper Sandler began coverage on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 price target for the company. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Finally, UBS Group decreased their target price on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research report on Friday, April 11th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $58.00.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.